During the corresponding time, Alpha Cognition Inc. recorded a revenue increase by 267.56 % year on year, sequentially revenue grew by 72.42 %. While revenue at the Alpha Cognition Inc.'s corporate clients
Alpha Cognition's Comment on Sales, Marketing and Customers
The company launched ZUNVEYL in the U.S. on March 19, 2025, targeting long-term care physicians treating elderly patients in nursing homes. The acetylcholinesterase inhibitor (AChEI) prescription market in the U.S. long-term care segment accounts for 36% of over 11 million prescriptions filled annually. The AChEI class includes Aricept, Exelon, Exelon Patch, Razadyne, Adlarity, Namzaric, and generic versions. The company is working to secure formulary coverage with U.S. payors and is negotiating with pharmacy benefit managers to address high patient turnover associated with existing AChEI therapies. It also plans to pursue strategic partnerships to expand physician promotional coverage. For international markets, the company intends to seek distribution partners in Europe, Latin America (Mexico, Central and South America), the Middle East, and Asia to navigate regulatory and distribution challenges. Additionally, the company is developing preclinical assets targeting cognitive impairment related to mild traumatic brain injury and mild-to-moderate Alzheimer’s disease.
Alpha Cognition’s Comment on Sales, Marketing and Customers
The company launched ZUNVEYL in the U.S. on March 19, 2025, targeting long-term care physicians treating elderly patients in nursing homes. The acetylcholinesterase inhibitor (AChEI) prescription market in the U.S. long-term care segment accounts for 36% of over 11 million prescriptions filled annually. The AChEI class includes Aricept, Exelon, Exelon Patch, Razadyne, Adlarity, Namzaric, and generic versions. The company is working to secure formulary coverage with U.S. payors and is negotiating with pharmacy benefit managers to address high patient turnover associated with existing AChEI therapies. It also plans to pursue strategic partnerships to expand physician promotional coverage. For international markets, the company intends to seek distribution partners in Europe, Latin America (Mexico, Central and South America), the Middle East, and Asia to navigate regulatory and distribution challenges. Additionally, the company is developing preclinical assets targeting cognitive impairment related to mild traumatic brain injury and mild-to-moderate Alzheimer’s disease.
Sources:
Alpha Cognition Inc.’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Alpha Cognition Inc.’s corporate clients.
For your research, we’ve provided 9 tables on Alpha Cognition Inc. corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
156.66 %